AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Scientists have identified two immunogenic domains of the prion protein PrP, which activate class II-restricted T cells and elicit antibody responses against the native molecule.
"Recent reports suggest that immunity against the prion protein (PrP) retards transmissible spongiform encephalopathies progression in infected mice. A major obstacle to the development of vaccines comes from the fact that PrP is poorly immunogenic, as it is seen as self by the host immune system. Additional questions concern the immune mechanisms involved in protection and the risk of eliciting adverse reactions in the central nervous system of treated patients," researchers in France report.
"Peptide-based vaccines offer an attractive strategy to overcome these difficulties," said Sylvie Gregoire and collaborators at INSERM E209, SEDAC Therapeutics, and the University of Paris. "We have undertaken the identification of the immunogenic regions of PrP, which trigger helper T cells (Th) associated with antibody production. Our results identify two main regions, one between the structured and flexible portion of PrP (98-127) and a second between alpha 1 and alpha 2 helix (143-187). Peptides (30-mer) corresponding ...
Source: HighBeam Research, Prion protein domains elicit antibody responses against native...